ALB and non-small cell lung carcinoma: ALI has previously been reported to be a significant independent predictor of response to nivolumab.13 The ALI was devised to assess the degree of systemic inflammation in patients with advanced NSCLC.26 Combined with the BMI, serum ALB, and NLR, the ALI serves as a more comprehensive indicator of systemic inflammation and therefore may be an important predictor of efficacy in patients treated with nivolumab.